Caris Life Sciences Sustainability Profile
Caris Life Sciences, a leading player in the precision medicine industry, is headquartered in France and operates extensively across Europe and North America. Founded in 2008, the company has made significant strides in advancing cancer care through its innovative molecular profiling services. Caris Life Sciences offers a unique suite of products, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor treatments to individual patients. Their commitment to precision medicine has positioned them as a trusted partner in oncology, with notable achievements in improving patient outcomes. With a focus on integrating advanced technologies and data analytics, Caris Life Sciences continues to set benchmarks in the industry, driving forward the future of personalised medicine.
DitchCarbon Score
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Caris Life Sciences's score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Caris Life Sciences's reported carbon emissions
In 2023, Caris Life Sciences reported a Scope 3 emissions intensity of approximately 0.00037 kg CO2e per € gross profit, reflecting their carbon footprint in relation to revenue. This figure represents a decrease from 2022, where the Scope 3 emissions intensity was about 0.00049 kg CO2e per € gross profit. However, Caris Life Sciences has not disclosed any absolute emissions data for Scope 1 or Scope 2, nor have they set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from a parent organization, indicating that their reported figures are independently sourced. As of now, Caris Life Sciences has not committed to any formal climate pledges or reduction initiatives, which places them in a broader industry context where many organisations are increasingly focusing on sustainability and carbon reduction strategies.
How Carbon Intensive is Caris Life Sciences's Industry?
How Carbon Intensive is Caris Life Sciences's Location?
Caris Life Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Caris Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
